McDermott Advises Egle Therapeutics and its Managers on its €40 Million Series A Financing Round
McDermott Will & Emery advised Egle Therapeutics which is a spin off of Institut Curie, an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, on its €40 million Series A financing round.
The round has been co-led by a pool of investors including LSP and BPI. Fund+, BioQube and Takeda Ventures, Inc. also participated in the round.
The new capital will be used primarily to advance the 2 lead assets into clinics, and further strengthen the internal drug pipeline.
The McDermott team who advised Egle Therapeutics and its managers comprised:
Emmanuelle Trombe & Anne-France Moreau, partners, and Ludivine Rabreau, associate
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.